Latest Adherium (ASX:ADR) News

Adherium Limited reports a surge in US commercial patients for its Hailie Smartinhaler platform, alongside strategic hires and a new product launch compatible with AstraZeneca inhalers, underpinning plans for a capital raise.

Adherium reports strong patient adoption and new US partnerships, positioning for significant expansion in 2025 with a target of 9,000 active users and entry into the Pharmacy Benefit Management sector.